MediWound Ltd. (NASDAQ:MDWD) Shares Bought by Silverberg Bernstein Capital Management LLC

Silverberg Bernstein Capital Management LLC grew its stake in MediWound Ltd. (NASDAQ:MDWD) by 8.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 91,884 shares of the biopharmaceutical company’s stock after buying an additional 7,200 shares during the period. MediWound accounts for 1.4% of Silverberg Bernstein Capital Management LLC’s investment portfolio, making the stock its 18th largest holding. Silverberg Bernstein Capital Management LLC owned about 0.85% of MediWound worth $1,636,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. Investor AB purchased a new position in shares of MediWound during the third quarter worth approximately $15,750,000. Rosalind Advisors Inc. grew its position in MediWound by 22.3% during the 3rd quarter. Rosalind Advisors Inc. now owns 628,050 shares of the biopharmaceutical company’s stock worth $11,343,000 after purchasing an additional 114,560 shares during the last quarter. ARK Investment Management LLC acquired a new position in MediWound in the third quarter valued at $1,806,000. State Street Corp raised its holdings in shares of MediWound by 219.6% in the third quarter. State Street Corp now owns 66,258 shares of the biopharmaceutical company’s stock valued at $1,197,000 after buying an additional 45,529 shares during the last quarter. Finally, Bank of New York Mellon Corp acquired a new stake in shares of MediWound during the second quarter worth about $342,000. 46.83% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $25.00 price objective on shares of MediWound in a research note on Friday, January 10th.

MediWound Price Performance

MDWD stock opened at $19.20 on Wednesday. The company’s 50 day simple moving average is $17.26 and its 200-day simple moving average is $17.71. MediWound Ltd. has a 12 month low of $11.04 and a 12 month high of $24.00. The firm has a market capitalization of $207.09 million, a PE ratio of -6.62 and a beta of 0.80.

MediWound (NASDAQ:MDWD) last released its quarterly earnings results on Tuesday, November 26th. The biopharmaceutical company reported ($0.98) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.50). MediWound had a negative return on equity of 82.17% and a negative net margin of 142.29%. During the same period last year, the firm earned ($0.24) earnings per share. As a group, sell-side analysts anticipate that MediWound Ltd. will post -2.6 earnings per share for the current year.

MediWound Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.